Abstract 3241
Background
Colorectal cancer (CRC) is one of the most common malignancies, and a leading cause of cancer death worldwide. Surgery is the only curative therapy available for locally advanced colon cancer (LACC), however, the disease is associated with a significant recurrence rate and even with adjuvant therapy its prognosis is far from satisfactory. Preoperative treatment strategy is an attractive concept in LACC because it has the theoretical advantages to eradicate micrometastases, to reduce tumor cell shedding during surgery, to allow the assessment of initial tumor response and could be better tolerated than adjuvant treatment. The results of the recently reported FOxTROT trial has shown that preoperative chemotherapy in LACC is feasible with no increase in surgical morbidity or mortality. The immune contexture of solid tumors has become an emerging hallmark of cancers. Recent evidences indicate that immune infiltrate (immunoscore) is an informative prognostic indicator in LACC. Moreover, it was demonstrated that immunoscore is also a stronger predictor of patient survival than microsatellite instability. Based on these considerations, we designed a window of opportunity study to determine the feasibility of nivolumab in the preoperative setting in pts with LACC.
Trial design
Pts will receive nivolumab at a flat dosage of 240 mgs every two weeks on Day -28 and Day-14 (+/- one day) prior to planned surgery on Day 0 or up to + 7 days. An initial 6-pts safety run-in cohort will be followed by an expansion cohort, with a planned accrual of 16 pts. Postoperatively, standard adjuvant chemotherapy will be administered as recommended by guidelines. Primary objective is to determine the safety and feasibility of Nivolumab in the preoperative setting. The exploratory primary objective is the rate of pathological complete tumor regression, as well as correlative studies to determine molecular and immunophenotypic changes in tumor and peripheral blood samples as potential biomarkers of toxicity/efficacy. Secondary objective are tumor response rate defined by RECIST, postoperative complications, relapse-free survival, overall survival and metabolic response changes evaluated by FDG-PET-CT scan prior to surgery.
Clinical trial identification
EudraCT: 2017-003739-12.
Legal entity responsible for the study
Società Campana di Immunoterapia Oncologica (SCITO).
Funding
Società Campana di Immunoterapia Oncologica (SCITO) with funding from BMS.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract